当前位置:首页 - 行情中心 - 奥翔药业(603229) - 财务分析 - 现金流量表

奥翔药业

(603229)

  

流通市值:80.87亿  总市值:80.87亿
流通股本:8.30亿   总股本:8.30亿

现金流量表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金659,187,022.28411,554,272.5200,368,882.05757,583,630.29
  收到的税费返还---41,625,214.13
  收到其他与经营活动有关的现金60,824,871.625,108,839.9959,666,816.6354,354,904.45
  经营活动现金流入小计720,011,893.88436,663,112.49260,035,698.68853,563,748.87
  购买商品、接受劳务支付的现金294,171,951.15197,944,336.8791,994,238.05331,550,529.09
  支付给职工以及为职工支付的现金165,425,717.97109,096,442.4765,627,999.79189,341,378.57
  支付的各项税费41,043,301.0833,479,216.210,427,254.1254,712,813.67
  支付其他与经营活动有关的现金71,725,311.3150,739,450.1689,939,819.42100,033,250.18
  经营活动现金流出的平衡项目0-0.0100
  经营活动现金流出小计572,366,281.51391,259,445.69257,989,311.38675,637,971.51
  经营活动产生的现金流量净额147,645,612.3745,403,666.82,046,387.3177,925,777.36
二、投资活动产生的现金流量:
  取得投资收益收到的现金19,243,464.16-5,947,942.72-
  处置固定资产、无形资产和其他长期资产收回的现金净额282,596.09282,596.09-39,600
  收到的其他与投资活动有关的现金28,562,110.5239,194,828.99-37,562,444.94
  投资活动现金流入小计48,088,170.7739,477,425.085,947,942.7237,602,044.94
  购建固定资产、无形资产和其他长期资产支付的现金81,485,874.1553,803,090.6934,810,651.22111,302,153.47
  投资支付的现金4,008,8162,004,4082,009,8962,249,550.74
  支付其他与投资活动有关的现金10,431,265.0211,994,265.02-44,019,277.76
  投资活动现金流出小计95,925,955.1767,801,763.7136,820,547.22157,570,981.97
  投资活动产生的现金流量净额-47,837,784.4-28,324,338.63-30,872,604.5-119,968,937.03
三、筹资活动产生的现金流量:
  取得借款收到的现金275,180,810.84229,390,810.8489,790,810.84270,100,000
  收到其他与筹资活动有关的现金32,715,711.7117,198,981.95-20,712,726.52
  筹资活动现金流入小计307,896,522.55246,589,792.7989,790,810.84290,812,726.52
  偿还债务支付的现金170,294,767.18170,100,00070,000,000300,000,000
  分配股利、利润或偿付利息支付的现金88,318,438.423,519,572.691,749,440.3384,215,258.69
  支付其他与筹资活动有关的现金114,400,313.3369,114,187.6833,124,760.0214,817,353.39
  筹资活动现金流出小计373,013,518.93242,733,760.37104,874,200.35399,032,612.08
  筹资活动产生的现金流量净额-65,116,996.383,856,032.42-15,083,389.51-108,219,885.56
四、汇率变动对现金及现金等价物的影响-2,547,447.625,776,044.163,875,717.8110,842,676.45
五、现金及现金等价物净增加额32,143,383.9726,711,404.75-40,033,888.9-39,420,368.78
  加:期初现金及现金等价物余额1,048,581,219.151,048,581,219.151,048,581,219.151,088,001,587.93
  期末现金及现金等价物余额1,080,724,603.121,075,292,623.91,008,547,330.251,048,581,219.15
补充资料:
  净利润-169,346,106.65-206,791,017.22
  资产减值准备-6,415,526.03-9,406,759.08
  固定资产和投资性房地产折旧-33,482,969.78-61,548,139.45
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-33,482,969.78-61,548,139.45
  无形资产摊销-1,113,789.73-2,109,632.65
  固定资产报废损失---149,775.73
  公允价值变动损失--545,324.37--5,499,523.61
  财务费用--1,113,816.55--3,634,494.71
  投资损失--14,311,078.41--22,864,552.69
  递延所得税--908,668.17--2,529,615.13
  其中:递延所得税资产减少--908,668.17--455,987.91
    递延所得税负债增加----2,073,627.22
  存货的减少--2,971,305.84--45,590,984.29
  经营性应收项目的减少--143,441,616.35--23,026,782.45
  经营性应付项目的增加--1,962,646.21--6,194,577.57
  现金的期末余额-1,075,292,623.9-1,048,581,219.15
  减:现金的期初余额-1,048,581,219.15-1,088,001,587.93
  现金及现金等价物的净增加额-26,711,404.75--39,420,368.78
公告日期2025-10-312025-08-292025-04-302025-04-30
审计意见(境内)标准无保留意见
TOP↑